{
  "title": "Paper_366",
  "abstract": "pmc Sci Rep Sci Rep 1579 scirep Scientific Reports 2045-2322 Nature Publishing Group PMC12484987 PMC12484987.1 12484987 12484987 41028240 10.1038/s41598-025-19798-7 19798 1 Article Discovery and molecular docking studies of nitrogen containing naphthyridine derivatives as potent HIV1 NNRTIs with anticancer potential Baicharoen Apisara 1 Vijitphan Pongsit 1 Patnin Suwicha 1 Reukngam Nanthawan 1 Khlaychan Panita 1 Kuno Mayuso 2 Chaivisuthangkura Apinya 2 Techasakul Supanna supanna@cri.or.th 1 Makarasen Arthit arthit@cri.or.th 1 1 https://ror.org/00nb6mq69 grid.418595.4 0000 0004 0617 2559 Department of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, 2 https://ror.org/04718hx42 grid.412739.a 0000 0000 9006 7188 Department of Chemistry, Faculty of Science, Srinakharinwirot University, 1 10 2025 2025 15 478255 32622 30 6 2025 10 9 2025 01 10 2025 02 10 2025 02 10 2025 © The Author(s) 2025 2025 https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access http://creativecommons.org/licenses/by-nc-nd/4.0/ Fourteen novel 2,4-disubstituted-1,6- and 1,7-naphthyridine derivatives were developed to enhance HIV-1 RT inhibition through molecular hybridization of NNRTIs. The compounds were synthesized from nicotinate analogues via nucleophilic substitution and Buchwald-Hartwig reactions. Among them, 2-cyanopyridinyl-1,6-naphthyridines 16a 16b 19a 50 50 16a 16b 19a 17a 50 16a 16b 19a Supplementary Information The online version contains supplementary material available at 10.1038/s41598-025-19798-7. Keywords Quinoline Naphthyridine Molecular docking HIV-1 Cytotoxic Anti-cancer Subject terms Cancer Chemical biology Chemistry Computational biology and bioinformatics Drug discovery https://doi.org/10.13039/501100007959 Chulabhorn Research Institute https://doi.org/10.13039/501100017170 Thailand Science Research and Innovation 49896/4759817 36824/4274395 Patnin Suwicha Makarasen Arthit pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement © Springer Nature Limited 2025 Introduction Acquired Immunodeficiency Syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV), a lentivirus belonging to the Retroviridae family, resulting in immunological failure 1 2 3 4 5 6 7 8 8 9 10 11 12 7 9 13 14 13 15 17 18 19 20 21 22 23 27 28 29 30 23 24 25 26 27 50 50 1  Fig. 1 The core structure of 2-amino-4-phenoxy quinoline derivatives ( a b c Results & discussion Synthesis In this study, the derivatives of 1,6-naphthyridine and 1,7-naphthyridine with the substituent groups at 2,4-positions were synthesized and evaluated for their biological activities, including the molecular docking study, in order to increase the potency of HIV-1 RT inhibition. For our synthetic route, the 2-phenylamino-4-phenyloxy-1,6- and 1,7-naphthyridines and the 2,4-diphenyloxy-1,6- and 1,7-naphthyridines would be achieved from nucleophilic substitution reactions of 2,4-dichloronaphthyridine intermediates 7 8 31 7 1 2 1 2 3 3 5 5 7 3 8 7 2 8 2  Fig. 2 Syntheses of 2,4-dichloro-1,6-naphthyridine ( 7 8 a 2 b c 3 With 2,4-dichloro-naphthyridines 7 8 3 a b 27 7 a b 9a 9b 1 10a 10b 8 9a 9b 9a 9b 11a 11b 12a 12b 10a 10b 13 a b 14 a b 13a 13b 7 14a 14b 8 9 a b 10 a b 15 a b 17 a b 3 16 a b 18 a b 9 a b 10 a b 16a 18a 19a 20a 4 21 19a 20a 16a 18a E Z 1 2 1  Fig. 3 Syntheses of naphthyridine derivatives 9 a b 17 a b 27 a 1 2 3 b 1 2 3 c 2 2 2 2 3  Table 1 The substituent groups at the 2- and 4-positions of 1,6- and 1,7-naphthyridine derivatives. Compound Ar 1 Ar 2 9a 10a 11a 12a 13a 14a 2,6-dimethyl-4-formylphenoxy - 9b 10b 11b 12b 13b 14b 2,6-dimethyl-4-cyanophenoxy -  15a 2,6-dimethyl-4-formylphenoxy 4-cyanophenyl  15b 2,6-dimethyl-4-cyanophenoxy 4-cyanophenyl  16a 2,6-dimethyl-4-formylphenoxy 5-cyanopyridinyl  16b 2,6-dimethyl-4-cyanophenoxy 5-cyanopyridinyl  17a 2,6-dimethyl-4-formylphenoxy 4-cyanophenyl  17b 2,6-dimethyl-4-cyanophenoxy 4-cyanophenyl  18a 2,6-dimethyl-4-formylphenoxy 5-cyanopyridinyl  18b 2,6-dimethyl-4-cyanophenoxy 5-cyanopyridinyl  Fig. 4 Syntheses of 2-cyanopyridinylamino-4-cyanovinylphenoxy-naphthyridine derivatives 19a 20a a 2 2 t HIV-1 RT inhibition assay To evaluate the biological activities of the targeted naphthyridines, the percentage inhibitory activities against HIV-1 RT were utilized at a 1 µM concentration using a reverse transcriptase assay with a colorimetric method. The results are illustrated in Fig. 5 15 18 a b 19 20 a 13 a b 14 a b 27 27 16 a b 18 a b 15 a b 17 a b 16a 16b 19a 18a 18b 20a 16 a b 18 a b 19a 20a 50 2 50 50 19a 50 50 50  Fig. 5 Structures and Inhibitory activity (%) of 13 18 a b 19a 20a a  Table 2 Half maximal inhibitory concentration (IC 50 16 a b 18 a b 19a 20a a Compounds IC 50 4-(2’,6’-dimethyl-4’-formylphenoxy)−2-(5’’-cyanopyridin-2’’ylamino)quinoline 1.930 4-(2’,6’-dimethyl-4’-cyanophenoxy)−2-(5’’-cyanopyridin-2’’ylamino)quinoline 1.220  16a 0.222  16b 0.218  18a 0.333  18b 0.634  19a 0.175  20a 0.301 NVP 1.053 EFV 0.058 RPV 0.063 a Molecular docking studies The molecular docking investigation examined the binding interactions of commercial medicines (NVP, EFV, ETR, and RPV) with the synthesized naphthyridine derivatives ( 13 18(a b) 19a 20a 6 3 In the comparison between compounds 13(a b) 14(a b) 13a 13b 13b 14a 14b 14a 14b 13b 14b In the comparison between compounds 15(a b) 17(a b) 15a 15b 15a 15b 17a 17b 17a 17b 15a 15b In the comparison between compounds 16(a b) 18(a b) 16a 16b 16a 16b 18a 18b 16a 16b 18a 18b Among all tested compounds, 19a 20a 19a 20a 19a Compared to the reference medications (NVP, EFV, ETR, and RPV), compounds 16a 16b 19a 20a 19a 20a 16a 16b 32 The molecular docking results aligned with biological activity data. 19a 16a 16b 19a 16a 16b 19a  Fig. 6 The overlay of the conformations of the naphthyridine derivatives, namely 13 18 a b 19a 20a  Table 3 Binding energies and interactions between Naphthyridine derivatives, commercial drugs (NVP, EFV, ETR, and RPV), and HIV-1 RT from molecular docking. Compound Binding energy (kcal/mol) a NOC b H-bond π- π stacking 13a −13.66 ± 0.08 155 ± 4 LYS103*, VAL106, TYR318 TYR188, TRP229 13b −13.98 ± 0.02 178 ± 5 SER105*, VAL106, TRP229*, TYR318 TYR188, TRP229 14a −13.17 ± 0.05 148 ± 6 LYS103*, VAL106, TYR318 TYR181, TYR188, PHE227, TRP229 14b −13.64 ± 0.02 171 ± 9 LYS101*, PRO225*, PHE227 TYR188, TYR318 15a −13.05 ± 0.15 115 ± 8 LYS101, PRO225*, PHE227 TYR181, TYR188, TRP229 15b −13.39 ± 0.15 104 ± 4 LYS101, PRO225*, PHE227 PHE227 16a −13.45 ± 0.03 101 ± 4 LYS101, PRO225*, PHE227 TYR181, TRP229 16b −13.61 ± 0.02 118 ± 8 LYS101, PRO225*, PHE227 TYR181, PHE227, TRP229 17a −13.51 ± 0.13 109 ± 10 LYS101, LYS101*, PRO225*, PHE227 TYR181, PHE227, TYR318 17b −13.63 ± 0.24 95 ± 5 LYS101, LYS101*, PRO225*, PHE227 TYR181, PHE227, TYR318 18a −13.14 ± 0.04 87 ± 10 LYS101, LYS101*, PRO225*, PHE227 TYR181, PHE227, TRP229 18b −13.28 ± 0.04 114 ± 9 LYS101, LYS101*, PRO225*, PHE227 TYR181, PHE227, TRP229 19a −14.54 ± 0.03 111 ± 6 LYS101, TYR188, PRO225*, PHE227 TYR181, TRP229 20a −14.20 ± 0.01 116 ± 6 LYS101, LYS101*, TYR188, PRO225*, PHE227 TYR181, TYR188, TRP229 NVP −8.39 ± 0.03 123 ± 5 LYS101, LYS103* - EFV −9.25 ± 0.02 126 ± 4 LYS101 - ETR −11.75 ± 0.02 124 ± 5 LYS101 TYR181, TYR188, TYR318 RPV −13.25 ± 0.02 125 ± 4 LYS101 TYR181, TRP229 *Carbon Hydrogen-bonding interaction. a b Molecular dynamics simulations Molecular dynamics (MD) simulations were conducted to assess the binding stability of selected ligands and their impact on the conformational dynamics of HIV-1 RT in an explicit solvent environment 32 35 16a 16b 19a 7 7 16a 16b 19a 16b 7 16b 19a 16a 16b 19a 7 16b 19a 16a 16a  Fig. 7 The analyses of MD simulations. ( A 16a 16b 19a B 16a 16b 19a C 16a 16b 19a Pharmacokinetics studies Pharmacokinetics defines the processes of drug absorption, distribution, metabolism, and excretion (ADME) in the body, providing essential information for the optimization of therapeutic regimens. The partition coefficient (logP) is a crucial metric for evaluating drug-likeness and pharmacological potential, offering a rapid and effective prediction of membrane permeability and systemic distribution 36 37 38 13 18(a b) 19a 20a 39 4 Molecular dynamics simulations indicated that RPV had the lowest RMSF values among all residues, implying the most stability at the local residue level. The RMSD and Rg values of the HIV-1 RT- 16b 19a 40 16a 16b 19a  Table 4 Molecular properties of ligands calculated by SwissADME software. Ligand Number of H-bond acceptors Number of H-bond donors LogP Number of rotatable bonds TPSA 2 Molecular weight (g/mol)  13a 6 0 4.67 6 78.38 426.46  13b 6 0 4.83 4 91.82 420.46  14a 6 0 4.69 6 78.38 426.46  14b 6 0 4.82 4 91.82 420.46  15a 5 1 3.99 5 87.90 394.43  15b 5 1 4.06 4 94.62 391.42  16a 6 1 3.28 5 100.79 395.42  16b 6 1 3.35 4 107.51 392.41  17a 5 1 3.99 5 87.90 394.43  17b 5 1 4.08 4 94.62 391.42  18a 6 1 3.31 5 100.79 395.42  18b 6 1 3.36 4 107.51 392.41  19a 6 1 3.81 5 107.51 418.45  20a 6 1 3.81 5 107.51 418.45 NVP 3 1 2.33 1 63.57 266.3 EFV 5 1 3.80 1 38.33 315.67 RPV 4 2 3.79 5 97.42 366.42 Lipinski’s rule of five states that molecular weight must be less than 500 Da, lipophilicity (logP) must be less than 5, H-bond donors must be less than 5, H-bond accepter must be less than 10. Other parameters were considered. For example, total polar surface area (TPSA) should be less than 140 Å, and the number of rotatable bonds should be less than 10. Cytotoxic activity In recent years, NNRTI drugs have demonstrated inhibitory activity not only against HIV-1 but also, to a lesser extent, against certain types of cancer. Based on this dual potential, the present study evaluated the cytotoxic effects of newly synthesized compounds ( 13 18 a b 19a 20a 13 18 a b 19a 20a 5 6 Cytotoxic evaluation of compounds 13–14(a-b) Compounds 13a 13b 13a 50 50 13b 13a 14a 14b 13a 14a 50 13b 14b Cytotoxic evaluation of compounds 15 and 17(a-b) Compound 15a 15b 17a 17b 15 17 a b Cytotoxic evaluation of compounds 16 and 18(a-b), 19a, and 20a Compound 16a 16b 18 a b 18a 50 50 18b 50 19a 20a 18a 20a Comparative analysis of compounds 16(a-b) and 19a with reference drugs (NVP, EFV, RPV) The reference medicines, namely NVP, EFV, and RPV, which are well known for their anti-HIV-1 reverse transcriptase (RT) activity, were tested for cytotoxicity. RPV revealed high cytotoxicity against MOLT-3 (4.3 µM), HeLa (11.3 µM), HL-60 (11.5 µM), and T47-D (15.1 µM), while EFV exhibited moderate activity against HL-60 (33.7 µM) and HeLa (46.2 µM). NVP was largely inactive, with all data reported as percentage cytotoxicity. Compounds 16a 16b 19a 16a 16b 19a 16a 16a Selectivity index (SI) of compounds (13–18(a-b), 19a, 20a) and the reference drugs (NVP, EFV, RPV) The selectivity index (SI) is widely used to evaluate the safety margin of bioactive compounds. SI values above 3 are considered indicative of selective anticancer potential in preliminary screening. From the cytotoxicity evaluation of compounds 13–18(a-b) 19a 20a 5 6 13(a-b) 14–18(a) 13–17(a) 13(b) 14(a) 15(a) 17(a) 13b 17a  Table 5 In vitro cytotoxic activity and selectivity index (SI) of 13 a b 18 a b 19a 20a Compounds Molecular weight (g/mol) Cell lines a 50 b 50 50 d HepG2 MOLT-3 HuCCA-1 A549 MRC-5  13a 426.47 60.7 ± 1.0 SI = 1.12 11.3 ± 2.7 SI = 6.03 42.2 ± 2.6 SI = 1.61 107.2 ± 2.6 SI = 0.64 68.1 ± 1.1  13b 420.47 74.7 ± 13.3 SI > 1.59 11.3 ± 2.2 SI > 10.52 32.4 ± 2.7 SI > 3.67 36.1 ± 0.6 SI > 3.29 > 118.9(43%) c  14a 426.47 53.9 ± 3.4 SI = 1.21 9.6 ± 1.1 SI = 6.80 21.7 ± 1.6 SI = 3.01 60.8 ± 1.0 SI = 1.07 65.3 ± 2.1  14b 420.47 > 118.9(34%) c > 118.9(16%) c > 118.9(0%) c > 118.9(8%) c > 118.9(0%) c  15a 394.43 > 126.8(49%) c 17.6 ± 7.8 SI > 7.20 102.7 ± 5.4 SI > 1.23 45.9 ± 5.5 SI > 2.76 > 126.8(27%) c  15b 391.43 > 127.7(1%) c > 127.7(9%) c > 127.7(0%) c > 127.7(0%) c > 127.7(0%) c  16a 395.42 > 126.4(30%) c 17.4 ± 3.8 SI > 7.26 > 126.4(6%) c > 126.4(36%) c > 126.4(24%) c  16b 392.42 > 127.4(10%) c 106.1 ± 20.9 SI > 1.20 > 127.4(11%) c > 127.4(21%) c > 127.4(24%) c  17a 394.43 > 126.8(38%) c 9.1 ± 2.0 SI > 13.93 > 126.8(33%) c > 126.8(26%) c > 126.8(15%) c  17b 391.43 > 127.7(31%) c > 127.7(16%) c > 127.7(3%) c > 127.7(0%) c > 127.7(19%) c  18a 395.42 23.8 ± 2.5 SI = 3.97 14.9 ± 5.6 SI = 6.35 > 126.4(33%) c 55.5 ± 5.5 SI = 1.70 94.6 ± 9.0  18b 392.42 > 127.4(42%) c > 127.4(8%) c > 127.4(33%) c > 127.4(36%) c > 127.4(25%) c  19a 418.46 > 119.5(4%) c > 119.5(8%) c > 119.5(4%) c > 119.5(1%) c > 119.5(0%) c  20a 418.46 9.6 ± 6.5 SI = 3.14 84.7 ± 30.5 SI = 0.36 5.6 ± 1.3 SI = 5.38 26.0 ± 0.6 SI = 1.16 30.1 ± 10.2 NVP 266.30 > 187.8(15%) c > 187.8(29%) c > 187.8(11%) c > 187.8(18%) c > 187.8(1%) c EFV 315.68 86.6 ± 3.9 SI = 1.10 24.6 ± 1.2 SI = 3.89 59.6 ± 2.4 SI = 1.60 60.2 ± 3.2 SI = 1.59 95.6 ± 6.0 RPV 365.44 87.6 ± 11.5 SI > 1.56 4.3 ± 0.5 SI > 31.81 61.5 ± 1.7 SI > 2.22 > 136.8(42%) c > 136.8(14%) c doxorubicin 543.52 0.6 ± 0.02 SI = 5.17 0.02 ± 0.0 SI = 155 0.9 ± 0.1 SI = 3.44 0.6 ± 0.1 SI = 5.17 3.1 ± 0.5 etoposide 588.56 49.9 ± 1.1 0.03 ± 0.02 - - - a b 50 c 50 d 50 50 50  Table 6 In vitro cytotoxic activity and selectivity index (SI) of 13 a b 18 a-b 19a 20a Compounds Molecular weight (g/mol) Cell lines a 50 b 50 50 d MDA-MB-231 S102 HeLa T47-D H69AR HL-60  13a 426.47 56.3 ± 3.7 SI = 1.21 69.8 ± 2.8 SI = 0.98 24.1 ± 0.4 SI = 2.83 35.9 ± 2.1 SI = 1.90 91.8 ± 2.9 SI = 0.74 17.1 ± 2.4 SI = 3.98  13b 420.47 73.2 ± 8.1 SI > 1.62 103.2 ± 4.4 SI > 1.15 24.4 ± 2.5 SI > 4.87 34.1 ± 2.2 SI > 3.49 76.0 ± 6.54 SI > 1.56 81.5 ± 19.5 SI > 1.46  14a 426.47 49.4 ± 6.7 SI = 1.32 67.6 ± 2.2 SI = 0.97 12.2 ± 0.7 SI = 5.35 26.1 ± 5.0 SI = 2.50 52.2 ± 1.6 SI = 1.25 10.4 ± 0.8 SI = 6.28  14b 420.47 > 118.9(22%) c > 118.9(6%) c > 118.9(24%) c > 118.9(0%) c > 118.9(0%) c > 118.9(24%) c  15a 394.43 89.9 ± 2.1 SI > 1.41 > 126.8(30%) c 31.6 ± 1.9 SI > 4.01 42.1 ± 3.9 SI > 3.01 > 126.8(26%) c 18.2 ± 3.4 SI > 6.97  15b 391.43 > 127.7(9%) c > 127.7(0%) c > 127.7(0%) c > 127.7(4%) c > 127.7(0%) c > 127.7(9%) c  16a 395.42 112.6 ± 6.2 > 126.4(24%) c > 126.4(49%) c > 126.4(27%) c > 126.4(28%) c 41.1 ± 14.2 SI > 3.08  16b 392.42 > 127.4(25%) c > 127.4(1%) c > 127.4(6%) c > 127.4(9%) c > 127.4(0%) c > 127.4(22%) c  17a 394.43 85.7 ± 8.0 SI > 1.48 > 126.8(0%) c 13.2 ± 0.7 SI > 9.61 > 126.8(47%) c > 126.8(4%) c 8.9 ± 2.1 SI > 14.25  17b 391.43 > 127.7(44%) c > 127.7(0%) c > 127.7(0%) c > 127.7(8%) c > 127.7(0%) c > 127.7 (11%) c  18a 395.42 74.0 ± 7.3 SI = 1.28 95.9 ± 2.9 SI = 0.99 > 126.4(42%) c > 126.4(22%) c > 126.4(14%) c > 126.4(23%) c  18b 392.42 > 127.4(24%) c > 127.4(40%) c > 127.4(40%) c > 127.4(44%) c > 127.4(34%) c > 127.4(0%) c  19a 418.46 > 119.5(1%) c > 119.5(0%) c > 119.5(13%) c > 119.5(7%) c > 119.5(3%) c > 119.5(0%) c  20a 418.46 16.4 ± 3.1 SI = 1.84 66.7 ± 10.2 SI = 0.45 66.9 ± 0.6 SI = 0.45 > 119.5(27%) c > 119.5(48%) c > 119.5(0%) c NVP 266.30 > 187.8(9%) c > 187.8(3%) c > 187.8(34%) c > 187.8(14%) c > 187.8(8%) c > 187.8(3%) c EFV 315.68 77.7 ± 6.6 SI = 1.23 93.5 ± 4.7 SI = 1.02 46.2 ± 1.3 SI = 2.07 59.2 ± 0.8 SI = 1.61 105.0 ± 3.4 SI = 0.91 33.7 ± 1.1 SI = 2.84 RPV 365.44 25.3 ± 3.0 SI > 5.41 22.5 ± 1.2 SI > 6.08 11.3 ± 1.2 SI > 12.11 15.1 ± 1.3 SI > 9.06 57.2 ± 2.0 SI > 2.39 11.5 ± 0.8 SI > 11.90 doxorubicin 543.52 2.5 ± 0.1 SI = 1.24 2.2 ± 0.0 SI = 1.41 0.4 ± 1.8 SI = 7.75 1.2 ± 0.0 SI = 2.58 34.3 ± 0.1 SI = 0.09 0.1 ± 0.0 SI = 31 etoposide 588.56 - - - - - 0.8 ± 0.1 a b 50 c 50 d 50 50 50 Materials and methods Materials The starting materials and reagents were purchased from Aldrich Company and Tokyo Chemical Industry. These materials and reagents were used without purification. The melting point was received from the SMP3 Stuart™ digital melting point apparatus from Bibby Sterlin, Ltd. (Stone, United Kingdom). All of the synthesized compounds were characterized by nuclear magnetic resonance (NMR) and mass spectrometry (MS). NMR spectra were recorded on Bruker Avance III HD 300 and 400 spectrometers. The 300 MHz instrument was used to obtain ¹H (300 MHz) and ¹³C (75 MHz) spectra, whereas the 400 MHz instrument was used to acquire ¹H (400 MHz) and ¹³C (100 MHz) spectra. High-resolution mass spectra data were received from a micrOTOF electrospray ionization time-of-flight mass spectrometer (Bruker Daltonics, Germany). HepG2 (hepatocarcinoma), HuCCA-1 (cholangiocarcinoma), MOLT-3 (acute lymphoblastic leukemia), H69AR (lung cancer, multidrug resistant), MRC-5 (normal embryonic lung cell), A549 (lung carcinoma), MDA-MB-231 (hormone-independent breast cancer), S102 (Thai liver cancer), HeLa (cervical carcinoma), T47-D (hormone-dependent breast cancer), and HL-60 cell lines (promyeloblast) were purchased from Hyclone Laboratories. Etoposide (purity 98%) and Doxorubicin (purity 98%) were purchased from Aldrich Company. Synthesis Procedure for the preparation of Methyl 4-acetamidonicotinate (3) To a solution of methyl 4-aminonicotinate (5.37 g, 35.3 mmol) in 1,4-dioxane (72.0 mL, 0.50 M) was added acetic anhydride (17.0 mL, 5.00 equiv), and it was stirred at room temperature for 41 h. The reaction mixture was concentrated in vacuo vacuo 3 1 3 13 3 m/z 9 11 2 3 + Procedure for the preparation of Ethyl 3-acetamidoisonicotinate (4) To a solution of ethyl 3-aminonicotinate (1.52 g, 9.16 mmol) in 1,4-dioxane (19.0 mL, 0.50 M) was added acetic anhydride (9.00 mL, 10.0 equiv), and it was stirred at room temperature for 12 h. The 50 mL of cool water was added to the reaction mixture and neutralized by saturated sodium hydrogen carbonate. The reaction mixture was extracted thrice with EtOAc. The combined organic layers were washed with water and brine and dried over with anhydrous sodium sulfate. The organic layers were concentrated in vacuo 4 1 3 J J J J 13 3 m/z 10 13 2 3 + Procedure for the preparation of 2,4-dichloro-1,6-naphthyridine (7) and 2,4-dichloro-1,7-naphthyridine (8) To a solution of N-acetyl nicotinate ( 3 4 vacuo vacuo 5 6 3 5 6 vacuo 7 8 2 4-dichloro-1 6-naphthyridine 7 3 1 3 J J 13 3 m/z 8 5 2 2 + 2 4-dichloro-1 7-naphthyridine 8 4 1 3 J J 13 3 m/z 8 5 2 2 + General procedure for the synthesis of 4-oxy-aryl Naphthyridine derivatives (9–10(a-b)) To a solution of dichloronaphthyridines ( 7 8 9a 10a 9b 10b 2 3 vacuo 4-(2´,6´,-dimethyl-4´-formylphenoxy)−2-chloro-1,6-naphthyridine (9a) 49% yield (791 mg) as yellow solid, started from 1.02 g (5.15 mmol) of 7 2 3 1 3 J J J 13 3 m/z 17 14 2 2 + 2-(2´,6´,-dimethyl-4´-formylphenoxy)−4-chloro-1,6-naphthyridine (11a) 2-oxy-aryl naphthyridine derivative as a side product of 9a 1 3 J J 13 3 m/z 17 14 2 2 + 4-(2´ 6´ -dimethyl-4´-formylphenoxy)−2-chloro-1 7-naphthyridine 10a) 8 2 3 1 3 J J J 13 3 m/z 17 14 2 2 + 2-(2´ 6´ -dimethyl-4´-formylphenoxy)−4-chloro-1 7-naphthyridine (12a) 10a 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-chloro-1,6-naphthyridine (9b) 48% yield (151 mg) as a yellow solid, started from 200 mg (1.00 mmol) of 7 2 3 1 3 J J 13 3 m/z 17 13 3 + 2-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−4-chloro-1,6-naphthyridine (11b) 2-oxy-aryl naphthyridine derivative as a side product of 9b 1 3 J J J 13 3 m/z 17 13 3 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-chloro-1,7-naphthyridine (10b) 86% yield (42.0 mg) as a white solid, started from 50.0 mg (0.250 mmol) of 8 2 3 1 3 J J J 13 3 m/z 17 13 3 + 10b General procedure for the synthesis of 2,4-dioxy-aryl Naphthyridine derivatives (13–14(a-b)) To a solution of dichloronaphthyridine ( 7 8 13a 14a 13b 14b 2 3 vacuo 2,4-di-(2ˊ,6ˊ- dimethyl-4ˊ-formylphenoxy)−1,6-naphthyridine (13a) 89% yield (204 mg) as a white solid, started from 107 mg (0.54 mmol) of 7 2 3 1 3 J J 13 3 m/z 26 23 2 4 + 2,4-di-(2ˊ,6ˊ- dimethyl-4ˊ-formylphenoxy)−1,7-naphthyridine (14a) 86% yield (190 mg) as a white solid, started from 104 mg (0.52 mmol) of 8 2 3 1 3 J J 13 3 m/z 26 23 2 4 + 2,4-di-(2ˊ,6ˊ- dimethyl-4ˊ-cyanophenoxy)−1,6-naphthyridine (13b) 78% yield (168 mg) as a white solid, started from 102 mg (0.51 mmol) of 7 2 3 1 3 J J 13 3 m/z 26 20 4 2 + 2,4-di-(2ˊ,6ˊ- dimethyl-4ˊ-cyanophenoxy)−1,7-naphthyridine (14b) 90% yield (28.0 mg) as a white solid, started from 20.0 mg (0.10 mmol) of 8 2 3 1 3 J J 13 3 m/z 26 21 4 2 + General procedure for the synthesis of 2-amino-aryl-4-oxy-aryl Naphthyridine derivatives (15–18(a-b)) To a solution of each compound 9–10(a-b) 15 17(a b 16 18(a b 2 2 3 vacuo 4-(2ˊ,6ˊ-dimethyl-4ˊ-formylphenoxy)−2-(4ˊˊ-cyanophenyl)-amino-1,6-naphthyridine (15a) 51% yield (42.6 mg) as a yellow solid, started from 65.7 mg (0.21 mmol) of 9a 2 2 3 1 3 J J J J J 13 3 m/z 24 19 4 2 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-(4ˊˊ-cyanophenyl)-amino-1,6-naphthyridine (15b) 32% yield (15.0 mg) as a white solid, started from 37.0 mg (0.12 mmol) of 9b 2 2 3 1 3 J J J J 13 3 m/z 24 18 5 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-(4ˊˊ-cyanophenyl)-amino-1,7-naphthyridine (17a) 40% yield (28.5 mg) as a yellow solid, started from 57.1 mg (0.18 mmol) of 10a 2 2 3 1 3 J J J J 13 3 m/z 24 19 4 2 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-(4ˊˊ-cyanophenyl)-amino-1,7-naphthyridine (17b) 70% yield (71.3 mg) as a yellow solid, started from 80.0 mg (0.26 mmol) of 10b 2 2 3 1 3 J J J J 13 3 m/z 24 18 5 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-formylphenoxy)−2-(5ˊˊ-cyanopyridin-2ˊˊ-ylamino)−1,6-naphthyridine (16a) 89% yield (458 mg) as a yellow solid, started from 200 mg (0.64 mmol) of 9a 2 2 3 1 J J J 13 3 m/z 23 18 5 2 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-(5ˊˊ-cyanopyridin-2ˊˊ-ylamino)−1,6-naphthyridine (16b) 72% yield (349 mg) as a yellow solid, started from 381 mg (1.23 mmol) of 9b 2 2 3 1 3 J J J J J 13 3 m/z 23 17 6 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-(5ˊˊ-cyanopyridin-2ˊˊ-ylamino)−1,7-naphthyridine (18a) 76% yield (192 mg) as a yellow solid, started from 200 mg (0.64 mmol) of 10a 2 2 3 1 3 J J J J 13 m/z 23 18 5 2 + 4-(2ˊ,6ˊ-dimethyl-4ˊ-cyanophenoxy)−2-(5ˊˊ-cyanopyridin-2ˊˊ-ylamino)−1,7-naphthyridine (18b) 54% yield (72.3 mg) as a yellow solid, started from 106 mg (0.34 mmol) of 10b 2 2 3 1 J J J 13 m/z 23 17 6 + General procedure for the synthesis of 2-amino-pyridinyl-4-phenoxy-vinyl-naphthyridine derivatives (19–20)a To a solution of 2-amino-pyridinyl-4-oxy-aryl-naphthyridine ( 16a 18a tert 2 2 vacuo 19a 20a 4-(4´-(2´´-(E, Z)-cyanovinyl)−2´,6´-dimethyl-phenoxy)−2-(5´´-cyanopyridin-2´´ylamino)-amino-1,6-naphthyridine (19a) 29% yield (10.8 mg) as a white solid, started from 35.4 mg (0.09 mmol) of 16a 2 2 1 3 J J J J J J J J J J J 13 3 m/z 25 19 6 + 4-(4´-(2´´-(E Z)-cyanovinyl)−2´ 6´-dimethyl-phenoxy)−2-(5´´-cyanopyridin-2´´ylamino)-amino-1 7-naphthyridine 20a) 18a 2 2 1 3 J J J J J J J 13 3 m/z 25 19 6 + HIV-1 RT inhibition assay The inhibition assay of HIV-1 RT involved the utilization of the template/primer hybrid poly(A) × oligo(dT)15, along with digoxigenin (DIG)- and biotin-labeled nucleotides. An antibody specific to DIG, conjugated to peroxidase (anti-DIG-POD), was employed, along with the peroxidase substrate ABTS. The quantities of digoxigenin (DIG)- and biotin-labeled dUTP incorporated into DNA serve as a measure of HIV-1 RT activity. The HIV-1 RT inhibition assay was conducted utilizing an RT assay kit (Roche Applied Science, Mannheim, Germany). The procedures for assessing RT inhibition were carried out according to the protocol provided with the kit 41 42 50 Molecular docking studies Ligand and protein structure preparation involved the utilization of four commercially available drugs (nevirapine, efavirenz, etravirine, and rilpivirine) and fourteen synthetic compounds of phenylamino-phenoxy-naphthyridine derivatives as ligands. The ligands were generated using Gaussian 16 and fully optimized with density functional theory (DFT) at the B3LYP/6-31G(d, p) level 43 44 45 Molecular dynamic simulations The molecular dynamics (MD) simulations were conducted using the GROMACS (v2022.3) software package (University of Groningen, Groningen, Netherlands) 46 47 48 16a 16b 19a 49 50 51 Pharmacokinetic parameter calculation In this study, SwissADME was employed to analyze the pharmacokinetic parameters, including absorption, distribution, metabolism, and excretion (ADME), and to screen drug-likeness and molecular properties based on Lipinski’s Rule of Five for the ligands. Cytotoxic activity The cell lines were seeded into a 96-well microplate (Costar No. 3599) at a density ranging from 5 × 10 3 4 2 52 53 2 52 50 50 50 54 54 55 Conclusions This study successfully synthesized a series of fourteen novel 2,4-disubstituted-1,6- and 1,7-naphthyridine derivatives through a molecular hybridization strategy utilizing commercially available non-nucleoside reverse transcriptase inhibitors (NNRTIs), specifically nevirapine (NVP), efavirenz (EFV), and rilpivirine (RPV). The synthetic route, comprising 4–6 steps from nicotinate analogues, utilized nucleophilic substitution reaction and the Buchwald-Hartwig reaction as the essential reactions. Among the synthesized compounds, 2-cyanopyridinyl-1,6-naphthyridines 16a 16b 19a 50 17a 50 Compounds 16a 16b 19a 16a 16b 19a 16a 16b 19a 16a 16b 19a Supplementary Information Below is the link to the electronic supplementary material.  Supplementary Material 1 Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements The authors gratefully acknowledge the Chulabhorn Research Institute for providing research equipment and facilitating the experimental work carried out in this study. Author contributions Conceptualization, A. M., M. K. and S.T.; Methodology, P.V., S.P., A.B., N.R. and P.K.; Formal analysis, A.B. and P.V.; Software, S.P. and M.K.; investigation, A.M., and S.P.; resources, A.M. and S.T.; Data curation, P.V. and A.C.; Validation A.M.; Writing-original draft preparation, A.B., P.V. and S.P.; Writing-review and editing, A. M, and S.P.; Visualization, A.M., A.B. and S.P.; Supervision, S.T.; Project administration, A.M. and S.T.; Funding acquisition, S.T. and S.P. All authors have read and agreed to the published version of the manuscript. Funding The authors are grateful to the Chulabhorn Research Institute and Thailand Science Research and Innovation (TSRI) for financial support (Grant No. 49896/4759817 and 36824/4274395). Data availability The data supporting this article have been included as part of the Electronic Supplementary Information. Declarations Competing interests The authors declare no competing interests. References 1. Luciw, P. A. Human immunodeficiency viruses and their replication in Virology 2. Quinn TC Global burden of the HIV pandemic Lancet 1996 348 9020 99 106 10.1016/S0140-6736(96)01029-X 8676726 Quinn, T. C. Global burden of the HIV pandemic. Lancet 348 8676726 10.1016/s0140-6736(96)01029-x 3. Kirschner DE Webb GF Understanding drug resistance for monotherapy treatment of HIV infection Bull. Math. Biol. 1997 59 4 763 785 10.1007/BF02458429 9214852 Kirschner, D. E. & Webb, G. F. Understanding drug resistance for monotherapy treatment of HIV infection. Bull. Math. Biol. 59 9214852 10.1007/BF02458429 4. Hammer SM A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS clinical trials group study 175 study team N Engl. J. Med. 1996 335 15 1081 1090 10.1056/NEJM199610103351501 8813038 Hammer, S. M. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS clinical trials group study 175 study team. N Engl. J. Med. 335 8813038 10.1056/NEJM199610103351501 5. Hogg RS Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART PLoS Med. 2006 3 9 e356 10.1371/journal.pmed.0030356 16984218 PMC1569883 Hogg, R. S. et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 3 16984218 10.1371/journal.pmed.0030356 PMC1569883 6. Palmer C HIV treatments and highly active antiretroviral therapy Aust Prescr 2003 26 3 59 61 10.18773/austprescr.2003.042 Palmer, C. HIV treatments and highly active antiretroviral therapy. Aust Prescr 26 7. Usach I Melis V Peris J Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability J. Int. AIDS Soc. 2013 16 1 1 14 10.7448/IAS.16.1.18567 24008177 PMC3764307 Usach, I., Melis, V. & Peris, J. Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. Int. AIDS Soc. 16 24008177 10.7448/IAS.16.1.18567 PMC3764307 8. Carpenter CCJ Antiretroviral therapy for HIV infection in 1998 JAMA 1998 280 1 78 86 10.1001/jama.280.1.78 9660368 Carpenter, C. C. J. Antiretroviral therapy for HIV infection in 1998. JAMA 280 9660368 10.1001/jama.280.1.78 9. Martins S Ramos M Fernandes P The current status of the NNRTI family of antiretrovirals used against HIV infection Curr. Med. Chem. 2008 15 11 1083 1095 10.2174/092986708784221467 18473804 Martins, S., Ramos, M. & Fernandes, P. The current status of the NNRTI family of antiretrovirals used against HIV infection. Curr. Med. Chem. 15 18473804 10.2174/092986708784221467 10. Zhou Z Lin X Madura J HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development Infect. Disord Drug Targets 2006 6 4 39 413 10.2174/187152606779025833 17168804 Zhou, Z., Lin, X. & Madura, J. HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development. Infect. Disord Drug Targets 6 10.2174/187152606779025833 17168804 11. Sluis-Cremer N Tachedjian G Mechanisms of Inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors Virus Res. 2008 134 1–2 147 156 10.1016/j.virusres.2008.01.002 18372072 PMC2745993 Sluis-Cremer, N. & Tachedjian, G. Mechanisms of Inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 134 18372072 10.1016/j.virusres.2008.01.002 PMC2745993 12. Nemr MTM Yousif MNM Barciszewski J Interaction of small molecules with polynucleotide repeats and frameshift site RNA Arch Pharm. (Weinheim) 2019 352 8 e1900062 10.1002/ardp.201900062 31169327 Nemr, M. T. M., Yousif, M. N. M. & Barciszewski, J. Interaction of small molecules with polynucleotide repeats and frameshift site RNA. Arch Pharm. (Weinheim) 352 31169327 10.1002/ardp.201900062 13. Mehellou Y De CE Twenty-six years of Anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 2009 53 2 521 538 10.1021/jm900492g 19785437 Mehellou, Y. & De, C. E. Twenty-six years of Anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 53 10.1021/jm900492g 19785437 14. Pedersen OS Pedersen EB Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom Antivir Chem. Chemother. 1999 10 6 285 314 10.1177/095632029901000601 10628805 Pedersen, O. S. & Pedersen, E. B. Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antivir Chem. Chemother. 10 10628805 10.1177/095632029901000601 15. John, R., Wang, S., Islam, M. D. & Kumarasiri, M. WO Patent 16. Hecht M Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation Oncol. Lett. 2017 15 1728 1736 29434868 10.3892/ol.2017.7523 PMC5776903 Hecht, M. et al. Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation. Oncol. Lett. 15 29434868 10.3892/ol.2017.7523 PMC5776903 17. Islam S Anti-leukaemic activity of rilpivirine is mediated by Aurora A kinase Inhibition Cancers 2023 15 4 1044 10.3390/cancers15041044 36831387 PMC9954146 Islam, S. et al. Anti-leukaemic activity of rilpivirine is mediated by Aurora A kinase Inhibition. Cancers 15 36831387 10.3390/cancers15041044 PMC9954146 18. Moustafa AH Novel guanidine derivatives targeting leukemia as selective src/abl dual inhibitors: design, synthesis and anti-proliferative activity Bioorg. Chem. 2024 147 107410 10.1016/j.bioorg.2024.107410 38688197 Moustafa, A. H. Novel guanidine derivatives targeting leukemia as selective src/abl dual inhibitors: design, synthesis and anti-proliferative activity. Bioorg. Chem. 147 38688197 10.1016/j.bioorg.2024.107410 19. Fadaly WAA Nemr MTM Abd El-Hameed AM Mohamed FEA Zidan TH Design and synthesis of new pyrazole hybrids linked to oxime and nitrate moieties as COX-2, EGFR L858R/T790M Bioorg. Chem. 2025 161 108563 10.1016/j.bioorg.2025.108563 40349531 Fadaly, W. A. A., Nemr, M. T. M., Abd El-Hameed, A. M., Mohamed, F. E. A. & Zidan, T. H. Design and synthesis of new pyrazole hybrids linked to oxime and nitrate moieties as COX-2, EGFR L858R/T790M Bioorg. Chem. 161 40349531 10.1016/j.bioorg.2025.108563 20. Nalli M New Indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar Inhibition of single and double HIV-1 mutant strains Eur. J. Med. Chem. 2020 208 112696 10.1016/j.ejmech.2020.112696 32883642 Nalli, M. et al. New Indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar Inhibition of single and double HIV-1 mutant strains. Eur. J. Med. Chem. 208 32883642 10.1016/j.ejmech.2020.112696 21. Jiang X Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors Commun. Chem. 2023 6 83 10.1038/s42004-023-00888-4 37120482 PMC10148624 Jiang, X. et al. Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. Commun. Chem. 6 37120482 10.1038/s42004-023-00888-4 PMC10148624 22. Chen X Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors Eur. J. Med. Chem. 2012 51 60 66 10.1016/j.ejmech.2012.02.019 22405288 Chen, X. et al. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. Eur. J. Med. Chem. 51 22405288 10.1016/j.ejmech.2012.02.019 23. Deo KD Singhvi IJ Murugesan S Vadnere GP Patil AV Design, synthesis and biological evaluation of novel Quinoline analogues as HIV-1 integrase inhibitor IJPSR 2020 11 3 1210 1223 Deo, K. D., Singhvi, I. J., Murugesan, S., Vadnere, G. P. & Patil, A. V. Design, synthesis and biological evaluation of novel Quinoline analogues as HIV-1 integrase inhibitor. IJPSR 11 24. Forezi LD Design, synthesis, in vitro and in Silico studies of novel 4-oxoquinoline ribonucleoside derivatives as HIV-1 reverse transcriptase inhibitors Eur. J. Med. Chem. 2020 194 112255 10.1016/j.ejmech.2020.112255 32244098 Forezi, L. D. et al. Design, synthesis, in vitro and in Silico studies of novel 4-oxoquinoline ribonucleoside derivatives as HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem. 194 32244098 10.1016/j.ejmech.2020.112255 25. Makarasen A Molecular Docking studies and synthesis of amino-oxy-diarylquinoline derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors Drug Res. 2019 69 12 671 682 10.1055/a-0968-1150 31698495 Makarasen, A. et al. Molecular Docking studies and synthesis of amino-oxy-diarylquinoline derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Drug Res. 69 10.1055/a-0968-1150 31698495 26. Techasakul, S. et al. WO Patent EP3676252A4. (2017). 27. Makarasen A Structural basis of 2-phenylamino-4-phenoxyquinoline derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors Molecules 2022 27 2 461 10.3390/molecules27020461 35056776 PMC8781960 Makarasen, A. et al. Structural basis of 2-phenylamino-4-phenoxyquinoline derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Molecules 27 35056776 10.3390/molecules27020461 PMC8781960 28. Lu JX Design, synthesis, anticancer activity and molecular Docking of quinoline-based dihydrazone derivatives RSC Adv. 2025 15 1 231 243 10.1039/D4RA06954D 39758910 PMC11694625 Lu, J. X. Design, synthesis, anticancer activity and molecular Docking of quinoline-based dihydrazone derivatives. RSC Adv. 15 39758910 10.1039/d4ra06954d PMC11694625 29. Zayed MF Quinazoline derivatives as targeted chemotherapeutic agents Cureus 2024 16 5 e60662 38899242 10.7759/cureus.60662 PMC11186210 Zayed, M. F. Quinazoline derivatives as targeted chemotherapeutic agents. Cureus 16 38899242 10.7759/cureus.60662 PMC11186210 30. Sahin C Mutlu D Erdem A Kilincarslan R Arslan S New cyclometalated iridium(III) complexes bearing substituted 2-(1H-benzimidazol-2-yl)quinoline: synthesis, characterization, electrochemical and anticancer studies Bioorg. Chem. 2024 15 107706 10.1016/j.bioorg.2024.107706 39128244 Sahin, C., Mutlu, D., Erdem, A., Kilincarslan, R. & Arslan, S. New cyclometalated iridium(III) complexes bearing substituted 2-(1H-benzimidazol-2-yl)quinoline: synthesis, characterization, electrochemical and anticancer studies. Bioorg. Chem. 15 10.1016/j.bioorg.2024.107706 39128244 31. Kocsi D Orthaber A Borbas KE Tuning the photophysical properties of luminescent lanthanide complexes through regioselective antenna fluorination Chem. Commun. 2022 58 48 6853 6356 10.1039/D2CC01229D 35616538 Kocsi, D., Orthaber, A. & Borbas, K. E. Tuning the photophysical properties of luminescent lanthanide complexes through regioselective antenna fluorination. Chem. Commun. 58 10.1039/d2cc01229d 35616538 32. Patnin S Cross-docking and molecular dynamic studies to achieve the potent antiviral HIV-1 nonnucleoside reverse transcriptase inhibitors Sci Ess J 2023 39 2 23 37 Patnin, S. et al. Cross-docking and molecular dynamic studies to achieve the potent antiviral HIV-1 nonnucleoside reverse transcriptase inhibitors. Sci Ess J 39 33. Ghafoor NA Kırboga KK Baysal O Suzek BE Silme RS Data mining and molecular dynamics analysis to detect HIV-1 reverse transcriptase RNase H activity inhibitor Mol. Divers. 2024 28 4 1869 1888 10.1007/s11030-023-10707-6 37561229 Ghafoor, N. A., Kırboga, K. K., Baysal, O., Suzek, B. E. & Silme, R. S. Data mining and molecular dynamics analysis to detect HIV-1 reverse transcriptase RNase H activity inhibitor. Mol. Divers. 28 37561229 10.1007/s11030-023-10707-6 34. Sathiyamani B Structural analysis and molecular dynamics simulation studies of HIV-1 antisense protein predict its potential role in HIV replication and pathogenesis Front. Microbiol. 2023 14 1152206 10.3389/fmicb.2023.1152206 37020719 PMC10067880 Sathiyamani, B. et al. Structural analysis and molecular dynamics simulation studies of HIV-1 antisense protein predict its potential role in HIV replication and pathogenesis. Front. Microbiol. 14 37020719 10.3389/fmicb.2023.1152206 PMC10067880 35. Terefe EM Ghosh A Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of phytochemicals isolated from Croton dichogamus Bioinform. Biol. Insights 2022 16 1 20 10.1177/11779322221125605 PMC9516429 36185760 Terefe, E. M. & Ghosh, A. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of phytochemicals isolated from Croton dichogamus Bioinform. Biol. Insights 16 10.1177/11779322221125605 PMC9516429 36185760 36. Kretsos K Miller MA Zamora-Estrada G Kasting GB Partitioning, diffusivity and clearance of skin permeants in mammalian dermis Int. J. Pharm. 2008 346 1–2 64 79 10.1016/j.ijpharm.2007.06.020 17703903 Kretsos, K., Miller, M. A., Zamora-Estrada, G. & Kasting, G. B. Partitioning, diffusivity and clearance of skin permeants in mammalian dermis. Int. J. Pharm. 346 17703903 10.1016/j.ijpharm.2007.06.020 37. Kelder J Grootenhuis PD Bayada DM Delbressine LP Ploemen J Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 1999 16 10 1514 1519 10.1023/A:1015040217741 10554091 Kelder, J., Grootenhuis, P. D., Bayada, D. M., Delbressine, L. P. & Ploemen, J. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16 10554091 10.1023/a:1015040217741 38. Waterbeemd VD Camenisch G Folkers G Chretien JR Raevsky OA Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors J. Drug Target. 1998 6 2 151 165 10.3109/10611869808997889 9886238 Waterbeemd, V. D., Camenisch, G., Folkers, G., Chretien, J. R. & Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 6 9886238 10.3109/10611869808997889 39. Daina A Michielin O Zoete V SwissADME A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules Sci. Rep. 2017 7 42717 10.1038/srep42717 28256516 PMC5335600 Daina, A., Michielin, O., Zoete, V. & SwissADME A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7 28256516 10.1038/srep42717 PMC5335600 40. Diaz-Delfin J Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother. 2012 56 6 3369 3375 10.1128/AAC.00104-12 PMC3370806 22430974 Diaz-Delfin, J. et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother. 56 10.1128/AAC.00104-12 PMC3370806 22430974 41. Ukkonen P Korpela J Suni J Hedman K Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays Eur J. Clin Microbiol Infect. Dis 1988 7 518 523 10.1007/BF01962603 3141160 Ukkonen, P., Korpela, J., Suni, J. & Hedman, K. Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays. Eur J. Clin Microbiol Infect. Dis 7 3141160 10.1007/BF01962603 42. Suzuki K Craddock BP Okamoto N Kano T Steigbigel RT Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase J. Virol. Methods 1993 44 2–3 189 198 10.1016/0166-0934(93)90054-U 7505283 Suzuki, K., Craddock, B. P., Okamoto, N., Kano, T. & Steigbigel, R. T. Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase. J. Virol. Methods 44 7505283 10.1016/0166-0934(93)90054-u 43. Frisch, M. J. et al. Gaussian 16, Revision, B.01; Gaussian Inc., Connecticut, (United States), (2016). 44. Morris GM AUTODOCK4 and AutoDockTools4: automated Docking with selective receptor flexibility J. Comput. Chem. 2009 30 16 2785 2791 10.1002/jcc.21256 19399780 PMC2760638 Morris, G. M. et al. AUTODOCK4 and AutoDockTools4: automated Docking with selective receptor flexibility. J. Comput. Chem. 30 19399780 10.1002/jcc.21256 PMC2760638 45. Kuroda DG Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase Nat. Chem. 2013 5 174 181 10.1038/nchem.1559 23422558 PMC3607437 Kuroda, D. G. et al. Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase. Nat. Chem. 5 23422558 10.1038/nchem.1559 PMC3607437 46. Abraham MJ Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers SoftwareX 2015 1 19 25 10.1016/j.softx.2015.06.001 Abraham, M. J. et al. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1 47. Case DA J. Chem. Inf. Model. 2023 63 20 6183 6191 10.1021/acs.jcim.3c01153 37805934 PMC10598796 Case, D. A. et al. J. Chem. Inf. Model. 63 37805934 10.1021/acs.jcim.3c01153 PMC10598796 48. He X Man VH Yang W Lee TS Wang J A fast and high-quality charge model for the next generation general amber force field J. Chem. Phys. 2020 153 11 114502 10.1063/5.0019056 32962378 PMC7728379 He, X., Man, V. H., Yang, W., Lee, T. S. & Wang, J. A fast and high-quality charge model for the next generation general amber force field. J. Chem. Phys. 153 32962378 10.1063/5.0019056 PMC7728379 49. Tian C FF19SB: Amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution J. Chem. Theory Comput. 2019 16 1 528 552 10.1021/acs.jctc.9b00591 31714766 Tian, C. et al. FF19SB: Amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J. Chem. Theory Comput. 16 31714766 10.1021/acs.jctc.9b00591 50. Mark P Nilsson L Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K J. Phys. Chem. A 2001 105 43 9954 9960 10.1021/jp003020w Mark, P. & Nilsson, L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J. Phys. Chem. A 105 51. Humphrey W Dalke A Schulten K Visual molecular dynamics J. Mol. Graph 1996 14 1 33 38 10.1016/0263-7855(96)00018-5 8744570 Humphrey, W., Dalke, A. & Schulten, K. Visual molecular dynamics. J. Mol. Graph 14 8744570 10.1016/0263-7855(96)00018-5 52. Doyly, A. & Griffiths, J. B. Mammalian cell culture-essential techniques. 62–64 (Wiley & Sons, 1997). 53. Tominaga H A water-soluble tetrazolium salt useful for colorimetric cell viability assay Anal. Commun. 1999 36 2 47 50 10.1039/a809656b Tominaga, H. et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal. Commun. 36 54. Badisa RH et. Al. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells Anticancer Res. 2009 29 8 2993 2996 19661306 PMC2885965 Badisa, R. H. et. Al. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res. 29 19661306 PMC2885965 55. Prayong P Barusrux S Weerapreeyakul N Cytotoxic activity screening of some Indigenous Thai plants Fitoterapia 2008 79 7–8 598 601 10.1016/j.fitote.2008.06.007 18664377 Prayong, P., Barusrux, S. & Weerapreeyakul, N. Cytotoxic activity screening of some Indigenous Thai plants. Fitoterapia 79 18664377 10.1016/j.fitote.2008.06.007 ",
  "metadata": {
    "Title of this paper": "Cytotoxic activity screening of some Indigenous Thai plants",
    "Journal it was published in:": "Scientific Reports",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484987/"
  }
}